SecBot SecBot
8-K ·Filed Jun 30, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001140361-26-026982
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The departure and replacement of the Principal Accounting Officer is a standard succession event with no expected disruption to financial reporting or operations. Monitor for any subsequent changes in the finance team, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.52
T+0 close · Jun 30, 2026 · via day close
Latest settled
−23.58%
T+60 · $2.69
Vs SPY
−26.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 1 $3.52entry
  2. T+1 · 5mo ago +9.09%α +9.22% · $3.84
  3. T+5 · 4mo ago +15.63%α +15.36% · $4.07
  4. T+20 · 4mo ago −10.80%α −8.61% · $3.14
  5. T+60 · 8w ago −23.58%α −26.45% · $2.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals disclosed the resignation of VP of Finance and Principal Accounting Officer John Militello, effective July 7, 2026, to pursue other opportunities. Joseph Manhede, the company's Associate VP of Corporate Controller since April 2026, was appointed as the new Principal Accounting Officer effective July 8, 2026. This is a routine internal succession with no material financial or operational impact.

Key Facts

  • John Militello resigned as VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, effective July 7, 2026.
  • Joseph Manhede appointed as Principal Accounting Officer effective July 8, 2026.
  • Manhede has served as Associate VP, Corporate Controller since April 2026 and has prior experience at Outlook Therapeutics, Amneal Pharmaceuticals, and Deloitte.
  • No new compensatory arrangements were entered into with Manhede in connection with the appointment.

Financial Impact

No financial impact; routine officer change with no compensation changes.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-026982
Document: 0001140361-26-026982-index-headers.html0001140361-26-026982
Document: 0001140361-26-026982-index.html0001140361-26-026982
Document: 0001140361-26-026982.txt0001140361-26-026982

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026